文献速递肝病消化道肿瘤与早癌

抗病毒治疗与乙型肝炎病毒相关肝细胞癌患者生存改善相关但应用不足:东西方真实世界经验

Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience.
PubMed 文献 · Aliment Pharmacol Ther · 2018-05-24

这项国际多中心队列研究纳入2000至2015年诊断的2518例乙型肝炎病毒相关肝细胞癌病例,约48%的患者曾接受抗病毒治疗,但仅17%在诊断时正在治疗(美国中心38%,亚洲中心11%)。接受抗病毒治疗者5年生存率高于未治疗者(肝硬化患者42%对25%,无肝硬化患者58%对36%),调整后死亡风险降低(诊断前用药HR 0.62,诊断后用药HR 0.79)。

要点

  • 仅17%的乙型肝炎病毒相关肝细胞癌患者在诊断时正在接受抗病毒治疗。
  • 抗病毒治疗者5年生存率高于未治疗者:肝硬化42%对25%,无肝硬化58%对36%。
  • 诊断前后启动抗病毒治疗均与死亡风险降低相关(调整HR 0.62和0.79)。

核心结论

  • 抗病毒治疗改善了乙型肝炎病毒相关肝细胞癌患者的总生存,跨癌症分期和治疗类型均一致,但在美国和亚洲中心均应用不足。
  • 需要扩大乙型肝炎病毒相关肝细胞癌患者的抗病毒治疗使用,并改善乙型肝炎病毒感染者的医疗衔接。

研究设计与样本

  • 国际多中心队列研究,纳入2000至2015年诊断的2518例乙型肝炎病毒相关肝细胞癌病例。
  • 使用Cox比例风险模型估计抗病毒治疗和肝硬化对患者死亡风险的HR及95%CI。

主要发现

  • 约48%的患者曾接受抗病毒治疗,但仅17%在肝细胞癌诊断时正在治疗(美国中心38%,亚洲中心11%)。
  • 根据美国标准,未接受抗病毒治疗的患者中超过60%有抗病毒治疗指征。
  • 肝硬化患者5年生存率低于无肝硬化患者(34%对46%,P < 0.001)。
  • 接受抗病毒治疗者5年生存率高于未治疗者:肝硬化患者42%对25%,无肝硬化患者58%对36%(两者P < 0.001)。
  • 抗病毒治疗与死亡风险降低相关:诊断前用药调整HR 0.62,诊断后用药调整HR 0.79(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti-viral therapy affects survival after HCC diagnosis. METHODS: This was an international multicentre cohort study of 2518 HBV-related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti-viral therapy and cirrhosis on patients' risk of death. RESULTS: Approximately, 48% of patients received anti-viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti-viral therapy would have been indicated for >60% of the patients not on anti-viral therapy based on American criteria. Patients with cirrhosis had lower 5-year survival (34% vs 46%; P < 0.001) while patients receiving anti-viral therapy had increased 5-year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P < 0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti-viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P < 0.001). CONCLUSIONS: Anti-viral therapy improved overall survival in patients with HBV-related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti-viral therapy in HBV-related HCC and better linkage-to-care for HBV patients are needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chen VL, Yeh ML, Le AK, et al. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther. 2018. PMID: 29797518. doi:10.1111/apt.14801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。